Pancreatic Cancer Research

ResearcherVeterans Health AdministrationActive in the last 2 years

Shishir Kumar Maithel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3591-8925; OpenAlex author ID A5027872333. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 1, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
99
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: 2 papers · 2014: 4 papers · 2015: 4 papers · 2016: 4 papers · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 3 papers · 2022: 1 paper · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 4 papers

Papers 41

  1. Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes… Co-author DOI 10.1002/jso.70387↗
  2. "Horses out of the barn": pancreatic ductal adenocarcinoma frequently extends beyond the grossly visible tumour, requiring microscopic rectification for accura… Co-author DOI 10.1111/his.70099↗
  3. High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
  4. Correction: Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0614↗
  5. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  6. Patient expectations about the oncologic benefit of pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.07.017↗
  7. Neighborhood Disadvantage is Associated with Worse Pathologic Response in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17024-2↗
  8. Lymph node metrics following neoadjuvant therapy to refine patient selection for adjuvant chemotherapy in resected pancreatic cancer: A multi-institutional ana… Co-author DOI 10.1002/jso.27798↗
  9. A Review of the Indications, Outcomes, and Postoperative Management After Total and Completion Pancreatectomy for Pancreatic Cancer: More Is Not Necessarily Be… Last author DOI 10.1016/j.suc.2024.04.012↗
  10. Top advances of the year: Pancreatic cancer. Last author DOI 10.1002/cncr.35031↗
  11. Accuracy of models to prognosticate survival after surgery for pancreatic cancer in the era of neoadjuvant therapy. Co-author DOI 10.1002/jso.27287↗
  12. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  13. Racial Disparity in Pathologic Response following Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: A Multi-Institutional Analysis from the Central Pancr… Co-author DOI 10.1245/s10434-022-12741-4↗
  14. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-instit… Co-author DOI 10.1245/s10434-022-11804-w↗
  15. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Co-author DOI 10.1097/sla.0000000000004471↗
  16. Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-19-0911↗
  17. ASO Author Reflections: Chemoradiation as the Mainstay of Therapy for Nonagenarians with Pancreatic Cancer. First author DOI 10.1245/s10434-020-09319-3↗
  18. Optimal timing and treatment strategy for pancreatic cancer. Co-author DOI 10.1002/jso.25976↗
  19. The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz? Last author DOI 10.1007/s11605-019-04377-9↗
  20. Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2020.01.004↗
  21. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  22. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. Co-author DOI 10.1172/jci.insight.130362↗
  23. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  24. Induction Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001353↗
  25. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  26. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Co-author DOI 10.1245/s10434-017-6322-4↗
  27. Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. Co-author DOI 10.1634/theoncologist.2017-0487↗
  28. Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. Last author DOI 10.1002/jso.24317↗
  29. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). Co-author DOI 10.1016/j.ijrobp.2016.05.010↗
  30. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Editio… Co-author DOI 10.1245/s10434-016-5093-7↗
  31. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. Co-author DOI 10.1634/theoncologist.2015-0316↗
  32. Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. Co-author DOI 10.1002/cam4.360↗
  33. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Co-author DOI 10.1002/jso.23921↗
  34. High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2014.11.004↗
  35. Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TN… Co-author DOI 10.1245/s10434-015-4861-0↗
  36. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-ins… Co-author DOI 10.1007/s11605-014-2567-4↗
  37. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer. Co-author DOI 10.1038/onc.2013.488↗
  38. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Co-author DOI 10.1097/sla.0000000000000890↗
  39. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-13-1996↗
  40. Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.28144↗
  41. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31829e2006↗

Trials 1

  1. Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision Principal investigator NCT01188109↗

Closest collaborators

The 25 strongest of 99 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David A. Kooby · 26 shared papers, 2013–2026 · strength 2.40
  2. Bassel F. El‐Rayes · 23 shared papers, 2013–2026 · strength 1.95
  3. Juan Manuel Sarmiento · 15 shared papers, 2014–2026 · strength 1.65
  4. Nipun B. Merchant · 11 shared papers, 2014–2025 · strength 1.53
  5. Jashodeep Datta · 7 shared papers, 2021–2025 · strength 1.19
  6. Daniel Erik Abbott · 9 shared papers, 2014–2025 · strength 1.13
  7. Gregory B. Lesinski · 5 shared papers, 2020–2026 · strength 0.99
  8. Syed Ameen Ahmad · 8 shared papers, 2014–2025 · strength 0.97
  9. Alexander A. Parikh · 7 shared papers, 2014–2025 · strength 0.94
  10. Gregory C. Wilson · 6 shared papers, 2014–2024 · strength 0.77
  11. Mihir Maheshkumar Shah · 3 shared papers, 2021–2026 · strength 0.64
  12. Chet W. Hammill · 4 shared papers, 2022–2025 · strength 0.64
  13. Olatunji Boladale Alese · 6 shared papers, 2016–2026 · strength 0.64
  14. Caitlin A. Hester · 3 shared papers, 2024–2025 · strength 0.63
  15. Mary P Martos · 3 shared papers, 2024–2025 · strength 0.63
  16. Walid Labib Shaib · 7 shared papers, 2016–2020 · strength 0.56
  17. Volkan N. Adsay · 9 shared papers, 2013–2026 · strength 0.55
  18. Syed Nabeel Zafar · 3 shared papers, 2023–2025 · strength 0.54
  19. Hong Joo Kim · 4 shared papers, 2019–2024 · strength 0.51
  20. Rebecca Anne Snyder · 3 shared papers, 2023–2025 · strength 0.50
  21. Burcu Saka · 7 shared papers, 2013–2026 · strength 0.47
  22. Robert C.G. Martin · 5 shared papers, 2014–2025 · strength 0.46
  23. Matthew R. Farren · 3 shared papers, 2020–2026 · strength 0.46
  24. Michael B. Ware · 3 shared papers, 2020–2026 · strength 0.46
  25. Ifeanyichukwu Chinedu Ogobuiro · 3 shared papers, 2023–2024 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.